TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04947436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Chest Wall Oscillation
Description: The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Chest Wall Oscillation
Description: The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical insufflation/exsufflation
Description: A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical insufflation/exsufflation
Description: A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.
Study: NCT00673127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole, Hydrocortisone and Dutasteride
Description: Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal
Study: NCT00020709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT02661503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procarbazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT02068196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling for Pre-existing immunity
Description: Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT02109107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia EZ6 Laser
Description: The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
Study: NCT03168399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU Explore
Description: PKU Explore is an unflavoured, powdered, phenylalanine-free, protein substitute, containing essential and non-essential amino acids, carbohydrate, sugar, vitamins, minerals, trace elements and the long chain polyunsaturated fatty acids (LCPs); arachidonic acid (AA) and docosahexaenoic acid (DHA).
Study: NCT01412632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil, propofol and citanest
Description: iv remifentanil iv propofol im citanest
Study: NCT01324700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High severity group: Escitalopram
Description: Participants within high severity group were stratified to receive escitalopram.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High severity group: Placebo
Description: Participants within high severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low severity group: Escitalopram
Description: Participants within low severity group were stratified to receive escitalopram.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low severity group: Placebo
Description: Participants within low severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
Study: NCT02251756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actinica, 0.8 mg/cm2, 1 application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actinica, 0.8 mg/cm2, 2 applications

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actinica, 2 mg/cm2, 1 application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actinica, 2 mg/cm2, 2 applications
Study: NCT03299413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly Mesenchymal stem cells
Description: Wharton Jelly Mesenchymal stem cells will be injected intravenously
Study: NCT00483080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv q3W or q1W NGR-hTNF 0.8 μg/m²
Study: NCT01398644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phlebotomy and erythrocytapheresis
Description: Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy and erythrocytapheresis
Description: Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
Study: NCT01612767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRO-Kinetic Energy Stent
Description: Coronary artery stent implant
Study: NCT04319614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Product
Description: A single dose of tranexamic acid, corresponding to 20 mg/kg in 100 ml saline, will be administered in the beginning of procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 100 ml of saline will be administered in the beginning of the procedure.
Study: NCT01891890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Description: Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
Study: NCT03436550

Intervention type: PROCEDURE
Intervention: mpMRI
Description: Multiparametric MRI

Intervention type: PROCEDURE
Intervention: ARFI US
Description: Acoustic radiation force impulse is a type of ultrasound elastography
Study: NCT01589549

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stromal cell therapy
Description: One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell therapy
Description: One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
Study: NCT03772600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM
Description: Use of Dexcom G6
Study: NCT02996318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel coated balloon (SeQuent Please)
Description: Paclitaxel coated balloon (SeQuent Please)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus coated balloon
Description: Sirolimus coated balloon
Study: NCT03515200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Capsule
Description: Given orally or nasogastrically (NG).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triple Therapy
Description: Given intrathecally (IT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally, nasogastrically (NG) or intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given intravenously (IV) or subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given orally or nasogastrically (NG).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given orally or nasogastrically (NG).
Study: NCT01143883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silverlon
Description: Silverlon dressings are gauze impregnated with silver ions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Dressing
Description: Standard dry gauze dressing
Study: NCT00741468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 2, 25 mg Proellex capsules administered daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP1A2 probe
Description: Caffeine (200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP2C9 probe
Description: Tolbutamide (250 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP2C19 probe
Description: Omeprazole (20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP2D6 probe
Description: Dextromethorphan (30 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP3A4 probe
Description: Midazolam (2mg)
Study: NCT01044836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD203
Description: Injectable form
Study: NCT00865137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus, modified release
Description: Oral
Study: NCT03906604

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Carpal Tunnel Procedure (open)
Description: Patients with bilateral CTS will have one side released with incisionless thread carpal tunnel release and the contralateral side released with the mini-open carpal tunnel release.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Carpal Tunnel Procedure (open)
Description: Patients with bilateral CTS will have one side released with incisionless thread carpal tunnel release and the contralateral side released with the mini-open carpal tunnel release.
Study: NCT03017521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-117
Description: TAS-117 16mg, daily
Study: NCT01846468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHW090
Description: 1 mg, 12.5 mg, 100 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHW090
Description: 1 mg, 12.5 mg, 100 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHW090
Description: 1 mg, 12.5 mg, 100 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHW090
Description: 1 mg, 12.5 mg, 100 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules
Study: NCT00428922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
Study: NCT02696928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemeter-Lumefantrine and MB (combination therapy)
Description: AL first 3 days MB next 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Artemeter-Lumefantrine (combination therapy)
Description: AL first 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemeter-Lumefantrine and Primaquine (combination therapy)
Description: AL first 3 days PQ next 14 days
Study: NCT03938688

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mesh placement with Transfascial Sutures
Description: Sutures that pass through the full thickness of the abdominal wall, which are used routinely for mesh fixation
Study: NCT02911259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction is set to -2 cmH2O
Description: Post-operative suction is set to -2 cmH2O (intervention).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction is set to -10 cmH2O
Description: Post-operative suction is set to -10 cmH2O (standard treatment).
Study: NCT00465543

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mint tea high in rosmarinic acid
Description: Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mint tea low in rosmarinic acid
Description: Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
Study: NCT03865394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Application of allogeneic ADSC stem cells in fibrin gel
Description: Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - single dose will be administered followed by weekly wound control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care in diabetic foot ulcer
Description: Chronic wounds in diabetic foot ulcer will be covered with fibrin gel followed by weekly wound control.
Study: NCT03124355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo sugar pill
Description: placebo single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Pill
Description: pyridostigmine bromide 30 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine Pill
Description: Galantamine hydrobromide 8mg single oral dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal stimulation
Description: Vagal stimulation will be given at 50 Hz during the tilt table tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal stimulation
Description: Vagal stimulation will be given at 50 Hz during the tilt table tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal stimulation
Description: Vagal stimulation will be given at 50 Hz during the tilt table tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham vagal stimulation
Description: Sham vagal stimulation will be given at 0.01 mA during the tilt table tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham vagal stimulation
Description: Sham vagal stimulation will be given at 0.01 mA during the tilt table tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham vagal stimulation
Description: Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
Study: NCT00681265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycerin
Description: Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 400/propylene glycol
Description: Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
Study: NCT03704012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol of massage therapy and kinesiotherapy
Description: Infants received massage and kinesiotherapy, applied by parents, twice a day; 15 minutes each.
Study: NCT01449747

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin (100mg, per oral) once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin (100mg, per oral) once a day.
Study: NCT02998619

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
Study: NCT03917537

Intervention type: GENETIC
Intervention: HNSCC patients have used Nivolumab
Description: Using Whole-Genome Analysis on Cancer Tissue of Patients with Platinum-refractory Head and Neck Squamous cell carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
Study: NCT01125566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
Study: NCT02649426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Paradise® Renal Denervation Ultrasound System
Description: Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
Study: NCT01840137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Strength Test
Description: A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Treadmill and muscle exercises.
Study: NCT02644330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transthoracic device closure
Description: minimally invasive transthoracic device closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical repair
Description: surgical repair with cardiopulmonary bypass
Study: NCT02013102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine Injection
Description: Decitabine Injection 20mg/m2/d\*5d, IV\> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d\*8d, IV\> 1h, one cycles per 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine Injection
Description: Decitabine Injection 20mg/m2/d\*5d, IV\> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d\*8d, IV\> 1h, one cycles per 4 weeks.
Study: NCT02398513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib 160 mg per oral
Study: NCT00006220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study: NCT01125566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: patients receive trastuzumab 2mg/kg intravenously every week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine
Description: patients receive vinorelbine 25mg/m² intravenously every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: patients receive vinorelbine 25mg/m² intravenously every week